Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: In search of an autoimmune aetiology

British Journal of Haematology

Volumn 117, Issue 3, 2002, Pages 541-545

  Gowans, Duncan ^a   O'Sullivan, Alan ^a   Rollinson, Sara ^b   Roddam, Phillipa ^b   Groves, Mike ^a   Fegan, Chris ^c   Morgan, Gareth ^b   Bowen, David ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Haplotype; HLA; IL 10; Myelodysplastic syndrome; TNF

Indexed keywords

CYTOKINE; DNA; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOIMMUNITY; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MYELODYSPLASIA; PATHOGENESIS; PRIORITY JOURNAL; REFRACTORY ANEMIA; SCORING SYSTEM; SIDEROBLASTIC ANEMIA;

ACUTE DISEASE; ALLELES; AUTOIMMUNE DISEASES; CYTOKINES; GENOTYPE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INTERLEUKIN-10; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036113150     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03452.x     Document Type: Article

References (22)

1. Mechanisms of glucocorticosteroid activity in patients with the preleukaemic syndrome (haematopoietic dysplasia)
2. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment
3. Two types of acquired idiopathic sideroblastic anaemia (AISA): A time-tested distinction
4. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
5. Interleukin-10: Biology, role in inflammation and autoimmunity
6. Polymorphic structure of the tumor necrosis factor (TNF) locus: An NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production
7. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus
8. Antithymocyte globulin for patients with myelodysplastic syndrome
9. Hematological response of patients with myelodysplastic syndrome (MDS) to antithymocyte globulin (ATG) treatment is associated with a loss of cd8+ t-cell mediated CFU-GM inhibition
10. Immunological abnormalities in myelodysplastic syndromes. 1 Serum immunoglobulins and autoantibodies
11. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia
12. Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities
13. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients
14. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia
15. HLA DR15 (DR2) is over-represented in myelodysplastic syndrome (MDS) and is associated with a response to immunosuppression
16. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes
17. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: An in vitro study
18. Immune function parameters at diagnosis in patients with myelodysplastic syndromes - Correlation with the FAB classification and prognosis
19. An investigation of polymorphism in the interleukin-10 gene promoter
20. Measurement of serum cytokine levels in patients with myelodysplastic syndromes
21. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome
22. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product